Safety of antithrombotic therapy in East Asian patients

被引:0
作者
Shinya Goto
Shinichi Goto
机构
[1] Tokai University School of Medicine,Department of Medicine (Cardiology)
来源
Internal and Emergency Medicine | 2021年 / 16卷
关键词
Anticoagulant; Bleeding complications; Asian;
D O I
暂无
中图分类号
学科分类号
摘要
Antithrombotic agents are widely used on the globe for prevention of thrombotic events such as atherothrombotic events and thromboembolic stroke in atrial fibrillation or for prevention and treatment of venous thromboembolism. However, the net clinical benefit of antithrombotic intervention may differ substantially in various sub-population of patients. Here, the authors attempt to address the risk of serious bleeding in East Asian as compared to the other regions of the world. The community-based epidemiological data suggest numerically higher risk of hemorrhage stroke in East Asian as compared to the globe. Importantly, the life-time risk of ischemic stroke in East Asia is higher than that of the globe. Regarding the serious bleeding risk in East Asians with the use of antithrombotic agents, various clinical trials and international registries provided conflicting information. It is hard to draw generalized conclusion, but there are some specific sub-population in East Asian with higher risk of specific serious bleeding events with the use of specific antithrombotic agents such as the risk of intra-cranial bleeding (ICH) with Vitamin K antagonists. Specific characteristics in East Asian such as higher prevalence of lacunar stroke may contribute higher risk of ICH in East Asian, but the detailed mechanism is still to be elucidated. In conclusion, further investigations are necessary to clarify the specific conditions where the risk of serious bleeding events in East Asian patients differ substantially compared to the global. In addition, further understanding of the mechanisms causing the different bleeding response in specific conditions in East Asian is awaited.
引用
收藏
页码:1443 / 1450
页数:7
相关论文
共 211 条
  • [1] Bhatt DL(2006)International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 180-189
  • [2] Steg PG(2020)Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study Heart Vessels 35 170-176
  • [3] Ohman EM(2011)One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE) Circ J 75 2598-2604
  • [4] Uchiyama S(2017)Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis Stroke 48 2494-2503
  • [5] Goto S(2015)Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs Lancet 386 303-310
  • [6] Origasa H(2015)Stroke prevention in atrial fibrillation: a systematic review JAMA 313 1950-1962
  • [7] Goto S(2010)Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2369-2429
  • [8] Ikeda Y(2014)2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 e1-e76
  • [9] Shimada K(2019)Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry Thromb Haemost 119 319-327
  • [10] Uchiyama S(2016)Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation J Thromb Thrombolysis 42 573-578